Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.51 |
| ▸ | SNCA | P37840 | 5/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | OGA | O60502 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3406868 | 0.86 | NAMPT (0.38) | NAMPTDRD2DRD3RXFP1LMNA | |
| SCHEMBL2294218 | 0.85 | NAMPT (0.51) | NAMPTSNCADRD2DRD3RXFP1 | |
| SCHEMBL2292781 | 0.84 | SNCA (0.39) | SNCADRD2DRD3LMNA | |
| SCHEMBL2299341 | 0.79 | NAMPT (0.54) | NAMPTSNCAOGALMNA | |
| SCHEMBL2290893 | 0.78 | NAMPT (0.53) | NAMPTSNCAMEN1KMT2AOGA | |
| SCHEMBL2295632 | 0.76 | SCD (0.58) | NAMPT | |
| SCHEMBL8098134 | 0.74 | NAMPT (0.49) | NAMPTSNCAOGALMNA | |
| SCHEMBL3407350 | 0.73 | NAMPT (0.46) | NAMPTSNCAOGALMNA | |
| SCHEMBL3406865 | 0.72 | LMNA (0.38) | DRD2DRD3RXFP1LMNAHRH4 | |
| SCHEMBL3403621 | 0.71 | AKT1 (0.39) | NAMPTDRD2DRD3RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003677-B2 | 2-heteroaryl-pyrrolo[3,4-c]pyrrole derivatives and their use as SCD inhibitors | SANOFI-AVENTIS (FR) | 2011-08-23 | — | — | US | claimed |
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | claimed |
| US-20110245263-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | disclosed |
| US-20110245263-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | disclosed |
| US-20110245263-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | disclosed |
| US-8003677-B2 | 2-heteroaryl-pyrrolo[3,4-c]pyrrole derivatives and their use as SCD inhibitors | SANOFI-AVENTIS (FR) | 2011-08-23 | — | — | US | disclosed |
| US-8003677-B2 | 2-heteroaryl-pyrrolo[3,4-c]pyrrole derivatives and their use as SCD inhibitors | SANOFI-AVENTIS (FR) | 2011-08-23 | — | — | US | disclosed |
| US-8003677-B2 | 2-heteroaryl-pyrrolo[3,4-c]pyrrole derivatives and their use as SCD inhibitors | SANOFI-AVENTIS (FR) | 2011-08-23 | — | — | US | disclosed |
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| WO-2008135141-A1 | 2 -HETEROARYL- PYRROLO [3, 4-C] PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SCD, SCD5, PYCR1 | NAMPT 1406/4885SNCA 1296/4885DRD2 1643/4885 |
| US-20110245263-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD | SCD, SCD5, PYCR1 | NAMPT 1694/4885SNCA 962/4885DRD2 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.